AGM statement & positive Q1 trading update
EKF Diagnostics Holdings plc has provided a positive trading update ahead of its AGM, confirming that trading for the year ending December 31, 2026, remains in line with management expectations. The company reported a cash position of £15.0 million as of May 8, with £2.1 million restricted in its Russian subsidiary, and continues to invest in growth initiatives and its share buyback program. Commercial traction for Hematology is strong, and β-HB sales in Life Sciences have exceeded expectations, with contract fermentation services showing steady improvement. EKF is on track to deliver revenue and adjusted EBITDA growth for FY 2026 in line with market expectations of £54.6 million and £13.6 million respectively.
Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes
AGM Statement
& Positive Q1 Trading update
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, provides an update to shareholders ahead of its Annual General Meeting ('AGM') today at Harwood Capital LLP, 6 Stratton Street, Mayfair, London W1J 8LD at 11.00 am.
Executive Chair's AGM statement
We are very pleased that trading to date for the year ended 31 December 2026 ("FY 2026") remains in-line with management expectations. As usual, we will provide an unaudited trading update for first six months of the current financial year ("H1 2026") at the end of July.
The completion of the first year of our Five-Year Strategic Development plan has firmly re-established the business with a simplified product offering, a greater commercial focus on the areas of strategic importance and an expanded marketing team to drive further organic growth.
Operational cash generation continues to be very strong alongside the continued internal investment for growth and the ongoing share buyback programme. Cash position as of 8 May is £15.0m, with £2.1m held by our Russian subsidiary and subject to regulatory restrictions, and we will continue to invest in areas that will further build on our growth strategy, and deliver long term shareholder value.
Commercial traction for Hematology remains strong with good ongoing instrument placement and increased consumable pull-through as expected. Within the Life Sciences division, β-HB sales have performed above management expectations and the pipeline and prospects for our contract fermentation services continues to grow showing continued steady improvement.
We remain excited about the prospects for the business and are on track to deliver growth at the revenue and adjusted EBITDA1 levels for FY 2026 in-line with market expectations2.
1adjusted earnings before interest, tax, depreciation and amortisation, share-based payments and exceptional items
²Management understands consensus revenue and Adjusted EBITDA forecasts for FY 2026 to be £54.6m and £13.6m respectively.
| EKF Diagnostics Holdings plc | www.ekfdiagnostics.com |
| Julian Baines, Executive Chair / Gavin Jones, Chief Executive Officer | via Walbrook PR |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: +44 (0)20 7496 3000 |
| Phil Davies / Patrick Weaver | |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0) 7407 804 654 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.